<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567502</url>
  </required_header>
  <id_info>
    <org_study_id>SPD422-401</org_study_id>
    <nct_id>NCT00567502</nct_id>
  </id_info>
  <brief_title>Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID速 (Anagrelide Hydrochloride) Compared to Other Treatments</brief_title>
  <official_title>A Non-Interventional, Post Authorisation Safety Study, to Continuously Monitor Safety and Pregnancy Outcomes in a Cohort of At-Risk Essential Thrombocythaemia (ET) Subjects Exposed to Xagrid Compared to Other Conventional Cytoreductive Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational safety study being conducted in Europe comparing patients taking
      Xagrid to patients taking other cytoreductive treatments. The plan is to enrol at least 750
      subjects taking Xagrid with up to 3000 subjects taking other cytoreductive therapies. The
      study will collect follow up data for 5 years for each patient enrolled that will focus on
      collecting data related to pre-defined events (PDEs) and Suspected Serious Adverse Reactions
      (SSARs).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With At Least One Pre-Defined Event (PDE), Deaths, Pregnancies</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Pre-defined events (PDEs) were evaluated whenever an event occurred and was defined by a panel of independent qualified physicians, blinded to cytoreductive therapy, validated all PDEs prior to analysis (Event Validation Panel). Non-PDE death only included deaths not recorded as outcome of another PDE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Suspected Serious Adverse Reaction (SSAR) Events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>SSAR: serious adverse event (SAE) that was considered related to cytoreductive therapy. SAE: any untoward medical occurrence that at any dose resulted in death, life-threatening (at the time of the event), in-patient hospitalization/prolongation of existing hospitalization (elective hospitalizations/procedures for pre-existing conditions that had not worsened were excluded), resulted in persistent or significant disability/incapacity or congenital abnormality/birth defect. Relatedness (suspected/not suspected) to XAGRID or other cytoreductive theraphy was determined by the investigator. As for SSARs, it was important to consider whether the events were related to XAGRID or other cytoreductive therapy. A participant was included in Xagrid or other treatment group based on treatment exposure, participants received Xagrid + Other was counted both in Xagrid and other treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Thrombohaemorrhagic Events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Event Rate of Thrombohaemorrhagic Events was calculated by dividing number of participants with events by total patient-year exposure. The reporting unit is per 100 participant-years of treatment exposure. Thrombohaemorrhagic Events is a composite endpoint of the PDEs myocardial infarction, angina, stroke, transient ischaemic attack, venous thromboembolic events, intermittent claudication/digital ischaemia, and major haemorrhagic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Count</measure>
    <time_frame>Baseline, Month 6,12,18, 24, 30, 36, 42, 48, 54, 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Exposure for Each Essential Thrombocythemia (ET) Therapy</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Total duration for each participant = sum of [stop date - start date + 1] across all periods of time where the specific treatment was taken during the study, where start date = registration/consent date for treatments started before registration/consent date and/or stop date withdrawal/final date for treatments ongoing at the time of withdrawal/end of study. Where a participant has multiple records of the same therapy on the same day, the therapy is counted once for that day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Dose for Each Essential Thrombocythemia (ET) Therapy</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Since the study is observational nature, interpreting the table is difficult due to inconsistencies in reporting the units of the dose.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">3647</enrollment>
  <condition>Thrombocythemia, Essential</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>XAGRID速 (anagrelide hydrochloride)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Xagrid + Other cytoreductive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Other cytoreductive</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving cytoreductive therapy for the treatment of at-risk essential
        thrombocytopenia (ET).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk ET patients

          -  Subjects who can give written informed consent.

          -  Subjects taking cytoreductive therapy

        Exclusion Criteria:

          -  Contraindications listed by the product being used.

          -  Patient cannot be participating in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Birgegard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Uppsala, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUS-Esbjerg Maematologisk afdelning</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2500</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde Sygehus</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>7000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jyvaskyla Central Hospital</name>
      <address>
        <city>Jyvaskyla</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil Cedex</city>
        <zip>95170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Cavale Blanche</name>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clemenceau</name>
      <address>
        <city>Caen cedex</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Simone Veil</name>
      <address>
        <city>Eaubonne</city>
        <zip>95602</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble Hopital Albert Michallon</name>
      <address>
        <city>Grenoble Cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lens</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Vincent de Paul</name>
      <address>
        <city>Lille cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Claude Huriez</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hopital Universitaire Dupuytren</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon-Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Nice Hopital de l Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel Dieu</name>
      <address>
        <city>Paris Cedex 4</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque - CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Heinrich, Dr. Brudler, Dr. Bangerter</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamatologisch-Onkologische Praxis</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Weniger und Dr. Bittrich</name>
      <address>
        <city>Erfurt</city>
        <zip>99085</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IORC GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>D-20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxis</name>
      <address>
        <city>Hornberg</city>
        <zip>34576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Schmitz and Steinmetz</name>
      <address>
        <city>Koln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis fur Hamatologie und Internistische Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamatologisch-Onkologische Praxis</name>
      <address>
        <city>Moers</city>
        <zip>47441</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schick</name>
      <address>
        <city>Muenchen</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamatologisch-Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambulante Chemotherapie</name>
      <address>
        <city>Munchen</city>
        <zip>81679</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamato-Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Munich</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis und Tagesklinik fur Internistische Onkologie</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritasklinik St. Theresia</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis fur Hamatologie und Internistische Onkologie</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamatologie und Onkologie</name>
      <address>
        <city>Weiden</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Yolanda Rodemer</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>26386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401 General Army Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Dunant Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens G.Gennimatas</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Hippocratio</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Laiko</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laikon General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Athens Attikon</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hygeia Hospital</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3rd Hospital of IKA</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Athens 多Attikon多</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Haematology</name>
      <address>
        <city>Lemessos</city>
        <zip>3304</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makarios Hospital</name>
      <address>
        <city>Nicchia</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patra</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Andrews General Hospital of Patra</name>
      <address>
        <city>Patra</city>
        <zip>26335</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaioniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ippokration Hospital D Clinic of Internal Medicine</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papageorgiou Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midland Regional Hospital</name>
      <address>
        <city>Tullamore</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Le Torrette</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Arezzo</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico Consorziale</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Perrino</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Civitanova Marche</city>
        <zip>62012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Fano</city>
        <zip>61132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Foggia</name>
      <address>
        <city>Foggia</city>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San salvatore</name>
      <address>
        <city>L'Aquila</city>
        <zip>67000</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto I</name>
      <address>
        <city>Mestre</city>
        <zip>30173</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera S. Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A.Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Monteluce</name>
      <address>
        <city>Perugia</city>
        <zip>06122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Salvatore</name>
      <address>
        <city>Pesaro</city>
        <zip>61100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale civile</name>
      <address>
        <city>Ragusa</city>
        <zip>97100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San camillo de Lellis</name>
      <address>
        <city>Rieti</city>
        <zip>02100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale oncologico regionale</name>
      <address>
        <city>Rionero in Vulture</city>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Nuova Regina Margherita</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Spirito</name>
      <address>
        <city>Rome</city>
        <zip>00193</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Padiglione ex-oncologico Ospedale S.Maria</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Gonzaga</name>
      <address>
        <city>Torino</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Molinette</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale civile</name>
      <address>
        <city>Vigevano</city>
        <zip>27029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Ostfold</name>
      <address>
        <city>Fredrikstad</city>
        <zip>1603</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Nordbyhagen</city>
        <zip>1474</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset Nord-Norge Hf</name>
      <address>
        <city>Tromso</city>
        <zip>1919</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servico de Hematologia</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4430</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Eloy</name>
      <address>
        <city>Barakaldo</city>
        <zip>48902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Josep Trueta</name>
      <address>
        <city>Gerona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Xeral Calde</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital JM Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falu Lasarett</name>
      <address>
        <city>Falun</city>
        <zip>79182</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicine Clinic</name>
      <address>
        <city>Gavle</city>
        <zip>SE 80187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lanssjukhuset Ryhov</name>
      <address>
        <city>Jonkoping</city>
        <zip>55185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ljungby Hospital Medical Clinic</name>
      <address>
        <city>Ljungby</city>
        <zip>341 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital MAS</name>
      <address>
        <city>Malmo</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Orebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sodersjukhuset - Medicinkliniken</name>
      <address>
        <city>Stockholm</city>
        <zip>11883</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lanssjukhuset Sundsvall - Harnosand</name>
      <address>
        <city>Sundsvall</city>
        <zip>85188</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uddevalla Hospital</name>
      <address>
        <city>Uddevalla</city>
        <zip>45180</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Hospital Uppsala</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrallasarettet - Medicinavdelningen</name>
      <address>
        <city>Vasteras</city>
        <zip>72189</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avon Haematology Unit BHOC</name>
      <address>
        <city>Bristol</city>
        <zip>BS9 1BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darlington Memorial Hospital</name>
      <address>
        <city>Darlington</city>
        <zip>DL3 6HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doncaster Royal Infirmary</name>
      <address>
        <city>Doncaster</city>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgina Oncology Unit</name>
      <address>
        <city>Dudley</city>
        <zip>DYI 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Paget University Hospital</name>
      <address>
        <city>Great Yarmouth</city>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE17EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Tyneside General Hospital</name>
      <address>
        <city>North Shields</city>
        <zip>NE298NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <zip>SY3 8QR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2007</study_first_posted>
  <results_first_submitted>March 25, 2015</results_first_submitted>
  <results_first_submitted_qc>October 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2015</results_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anagrelide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants who were newly diagnosed (received no treatment at the time of study registration) or previously diagnosed with essential thrombocythemia (ET), receiving or continuing previous cytoreductive therapy were recruited in the study</recruitment_details>
      <pre_assignment_details>Due to the non-interventional nature of the study, participants could be receiving XAGRID, XAGRID+Other (Cytoreductives), other (cytoreductives) and no essential thrombocythemia (ET) therapy. During the study participants could change the treatments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>XAGRID Only</title>
          <description>Participants who received XAGRID at a dose and mode of administration managed as per investigator's discretion and the relevant Summary of Product Characteristics (SmPC) at the time of registering into the study for a 5 year observation period, during which participants were able to switch treatments per investigator's discretion</description>
        </group>
        <group group_id="P2">
          <title>XAGRID+Other (Cytoreductives)</title>
          <description>Participants who received XAGRID+Other (Cytoreductives) at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study for a 5 year observation period, during which participants were able to switch treatments per investigator's discretion. Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
        </group>
        <group group_id="P3">
          <title>Other (Cytoreductives)</title>
          <description>Participants who received other (Cytoreductives) at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study for a 5 year observation period, during which participants were able to switch treatments per investigator's discretion. Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
        </group>
        <group group_id="P4">
          <title>No Essential Thrombocythemia (ET) Therapy</title>
          <description>Participants who were not receiving any cytoreductive treatment for at least 28 consecutive days at the time of registering into the study for a 5 year observation period, during which participants were able to switch treatments per investigators discretion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="804"/>
                <participants group_id="P2" count="141"/>
                <participants group_id="P3" count="2666"/>
                <participants group_id="P4" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Initiated Treatment</title>
              <participants_list>
                <participants group_id="P1" count="804"/>
                <participants group_id="P2" count="141"/>
                <participants group_id="P3" count="2666"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="563"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="1758"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="241"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="908"/>
                <participants group_id="P4" count="87"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="351"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="360"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="134"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant request</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor request</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never Initiated Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="72"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>First Treatment Safety Population included all participants who received at least 1 dose of cytoreductive treatment. Data of 2 participants were missing in the Other (Cytoreductives) treatment arm.</population>
      <group_list>
        <group group_id="B1">
          <title>XAGRID Only</title>
          <description>Participants who received XAGRID at a dose and mode of administration managed as per investigator's discretion and the relevant Summary of Product Characteristics (SmPC) at the time of registering into the study for a 5 year observation period, during which participants were able to switch treatments per investigator's discretion.</description>
        </group>
        <group group_id="B2">
          <title>XAGRID+Other (Cytoreductives)</title>
          <description>Participants who received XAGRID along with Other cytoreductives drugs at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study for a 5 year observation period, during which participants were able to switch treatments per investigator's discretion. Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
        </group>
        <group group_id="B3">
          <title>Other (Cytoreductives)</title>
          <description>Participants who received other (Cytoreductives) at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study for a 5 year observation period, during which participants were able to switch treatments per investigator's discretion. Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
        </group>
        <group group_id="B4">
          <title>No Essential Thrombocythemia (ET) Therapy</title>
          <description>Participants who were not receiving any cytoreductive treatment for at least 28 consecutive days at the time of registering into the study for a 5 year observation period, during which participants were able to switch treatments per investigator's discretion.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="804"/>
            <count group_id="B2" value="141"/>
            <count group_id="B3" value="2664"/>
            <count group_id="B4" value="38"/>
            <count group_id="B5" value="3647"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="14.99"/>
                    <measurement group_id="B2" value="59.9" spread="13.74"/>
                    <measurement group_id="B3" value="67.4" spread="13.05"/>
                    <measurement group_id="B4" value="64.3" spread="14.26"/>
                    <measurement group_id="B5" value="64.4" spread="14.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than (&lt;) 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="575"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="913"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="1591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-&lt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="897"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="1073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than equal to (&gt;=)75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="854"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="501"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="1632"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="2238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="303"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="1032"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="1409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With At Least One Pre-Defined Event (PDE), Deaths, Pregnancies</title>
        <description>Pre-defined events (PDEs) were evaluated whenever an event occurred and was defined by a panel of independent qualified physicians, blinded to cytoreductive therapy, validated all PDEs prior to analysis (Event Validation Panel). Non-PDE death only included deaths not recorded as outcome of another PDE.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>First Treatment Safety Population included participants who received cytoreductive therapy at registration. All events/data were allocated to the treatment that a participant was receiving at the time of the event/assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>XAGRID Only</title>
            <description>Participants who received XAGRID at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study or after switching from another treatment any time during the 5 year observation period.</description>
          </group>
          <group group_id="O2">
            <title>XAGRID+Other (Cytoreductives)</title>
            <description>Participants who received XAGRID+Other (Cytoreductives) at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study or after switching from another treatment any time during the 5 year observation period. Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
          </group>
          <group group_id="O3">
            <title>Other (Cytoreductives)</title>
            <description>Participants who received other (Cytoreductives) at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study or after switching from another treatment any time during the 5 year observation period. Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least One Pre-Defined Event (PDE), Deaths, Pregnancies</title>
          <description>Pre-defined events (PDEs) were evaluated whenever an event occurred and was defined by a panel of independent qualified physicians, blinded to cytoreductive therapy, validated all PDEs prior to analysis (Event Validation Panel). Non-PDE death only included deaths not recorded as outcome of another PDE.</description>
          <population>First Treatment Safety Population included participants who received cytoreductive therapy at registration. All events/data were allocated to the treatment that a participant was receiving at the time of the event/assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="804"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="2666"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiomyopathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other cardiovascular symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="8.5"/>
                    <measurement group_id="O3" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient ischemic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Mucocutaneous Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary fibrosis/ Interstitial pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venous thromboembolic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermittent Claudication/ digital ischaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transformations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelofibrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelodysplasia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute leukaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other leukaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other transformations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major haemorrhagic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhabdomyolysis/ myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-haematological malignancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-PDE death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pregnancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombohaemorrhagic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1"/>
                    <measurement group_id="O2" value="3.5"/>
                    <measurement group_id="O3" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major thrombotic events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arterial events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="2.8"/>
                    <measurement group_id="O3" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Thrombohaemorrhagic Events</title>
        <description>Event Rate of Thrombohaemorrhagic Events was calculated by dividing number of participants with events by total patient-year exposure. The reporting unit is per 100 participant-years of treatment exposure. Thrombohaemorrhagic Events is a composite endpoint of the PDEs myocardial infarction, angina, stroke, transient ischaemic attack, venous thromboembolic events, intermittent claudication/digital ischaemia, and major haemorrhagic events.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Overall Treatment Safety Population. As participant could switch between therapies a participant with an event could be allocated to more than one therapy group. Participants analyzed included who were exposed to the specific treatment any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XAGRID Only</title>
            <description>Participants who received XAGRID at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study or after switching from another treatment any time during the 5 year observation period.</description>
          </group>
          <group group_id="O2">
            <title>XAGRID+Other (Cytoreductives)</title>
            <description>Participants who received XAGRID+Other (Cytoreductives) at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study or after switching from another treatment any time during the 5 year observation period. Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
          </group>
          <group group_id="O3">
            <title>Other (Cytoreductives)</title>
            <description>Participants who received other (Cytoreductives) at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study or after switching from another treatment any time during the 5 year observation period. Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
          </group>
          <group group_id="O4">
            <title>No Essential Thrombocythemia (ET) Therapy</title>
            <description>Participants who were not receiving any cytoreductive treatment for at least 28 consecutive days at the time of registering into the study for a 5 year observation period, during which participants were able to switch treatments per investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Thrombohaemorrhagic Events</title>
          <description>Event Rate of Thrombohaemorrhagic Events was calculated by dividing number of participants with events by total patient-year exposure. The reporting unit is per 100 participant-years of treatment exposure. Thrombohaemorrhagic Events is a composite endpoint of the PDEs myocardial infarction, angina, stroke, transient ischaemic attack, venous thromboembolic events, intermittent claudication/digital ischaemia, and major haemorrhagic events.</description>
          <population>Overall Treatment Safety Population. As participant could switch between therapies a participant with an event could be allocated to more than one therapy group. Participants analyzed included who were exposed to the specific treatment any time during the study.</population>
          <units>participants/100 participant-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1127"/>
                <count group_id="O2" value="451"/>
                <count group_id="O3" value="2909"/>
                <count group_id="O4" value="645"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75"/>
                    <measurement group_id="O2" value="2.86"/>
                    <measurement group_id="O3" value="2.60"/>
                    <measurement group_id="O4" value="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Count</title>
        <time_frame>Baseline, Month 6,12,18, 24, 30, 36, 42, 48, 54, 60</time_frame>
        <population>Overall Treatment Safety population, Here n = participants evaluable at specified time-points. As participant could switch between therapies a participant with an event could be allocated to more than one therapy group. Participants analyzed included who were exposed to the specific treatment any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XAGRID Only</title>
            <description>Participants who received XAGRID at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study or after switching from another treatment any time during the 5 year observation period.</description>
          </group>
          <group group_id="O2">
            <title>XAGRID+Other (Cytoreductives)</title>
            <description>Participants who received XAGRID+Other (Cytoreductives) at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study or after switching from another treatment any time during the 5 year observation period. Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
          </group>
          <group group_id="O3">
            <title>Other (Cytoreductives)</title>
            <description>Participants who received other (Cytoreductives) at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study or after switching from another treatment any time during the 5 year observation period.Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
          </group>
          <group group_id="O4">
            <title>No Essential Thrombocythemia (ET) Therapy</title>
            <description>Participants who were not receiving any cytoreductive treatment for at least 28 consecutive days at the time of registering into the study for a 5 year observation period, during which participants were able to switch treatments per investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Count</title>
          <population>Overall Treatment Safety population, Here n = participants evaluable at specified time-points. As participant could switch between therapies a participant with an event could be allocated to more than one therapy group. Participants analyzed included who were exposed to the specific treatment any time during the study.</population>
          <units>10^9 per Liter (10^9/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1127"/>
                <count group_id="O2" value="451"/>
                <count group_id="O3" value="2909"/>
                <count group_id="O4" value="645"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n = 671, 120, 2279,136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486.90" spread="210.106"/>
                    <measurement group_id="O2" value="542.77" spread="250.440"/>
                    <measurement group_id="O3" value="471.29" spread="201.620"/>
                    <measurement group_id="O4" value="837.23" spread="377.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n = 777, 145, 2469, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1093.73" spread="17634.779"/>
                    <measurement group_id="O2" value="521.44" spread="266.512"/>
                    <measurement group_id="O3" value="439.44" spread="153.766"/>
                    <measurement group_id="O4" value="545.30" spread="202.936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n= 739, 158, 2400, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="969.61" spread="14404.677"/>
                    <measurement group_id="O2" value="516.66" spread="245.789"/>
                    <measurement group_id="O3" value="436.64" spread="154.958"/>
                    <measurement group_id="O4" value="501.46" spread="275.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n= 706, 170, 2231, 86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1612.14" spread="22193.573"/>
                    <measurement group_id="O2" value="541.78" spread="706.564"/>
                    <measurement group_id="O3" value="432.99" spread="145.694"/>
                    <measurement group_id="O4" value="476.72" spread="245.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n= 673, 181, 2106, 119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="865.09" spread="11047.483"/>
                    <measurement group_id="O2" value="492.67" spread="194.534"/>
                    <measurement group_id="O3" value="1025.11" spread="15888.471"/>
                    <measurement group_id="O4" value="499.29" spread="249.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 (n= 642, 183, 2001, 116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418.97" spread="159.129"/>
                    <measurement group_id="O2" value="467.37" spread="170.733"/>
                    <measurement group_id="O3" value="693.30" spread="8293.353"/>
                    <measurement group_id="O4" value="467.54" spread="255.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n= 628, 167, 1917, 124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423.10" spread="153.278"/>
                    <measurement group_id="O2" value="1138.81" spread="8787.658"/>
                    <measurement group_id="O3" value="1221.09" spread="20612.960"/>
                    <measurement group_id="O4" value="462.06" spread="256.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42 (n= 597, 161, 1799, 138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="831.62" spread="10257.081"/>
                    <measurement group_id="O2" value="466.83" spread="205.575"/>
                    <measurement group_id="O3" value="1898.48" spread="26724.419"/>
                    <measurement group_id="O4" value="463.52" spread="271.690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (n= 581, 167, 1735, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2461.07" spread="28879.771"/>
                    <measurement group_id="O2" value="443.91" spread="173.453"/>
                    <measurement group_id="O3" value="1360.17" spread="20669.182"/>
                    <measurement group_id="O4" value="457.44" spread="250.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 54 (n= 557, 164, 1644, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.93" spread="145.601"/>
                    <measurement group_id="O2" value="447.17" spread="171.608"/>
                    <measurement group_id="O3" value="1771.77" spread="25187.992"/>
                    <measurement group_id="O4" value="408.41" spread="254.971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 523, 167, 1586, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1174.87" spread="17473.437"/>
                    <measurement group_id="O2" value="466.31" spread="193.689"/>
                    <measurement group_id="O3" value="1362.94" spread="19098.693"/>
                    <measurement group_id="O4" value="425.22" spread="268.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Exposure for Each Essential Thrombocythemia (ET) Therapy</title>
        <description>Total duration for each participant = sum of [stop date - start date + 1] across all periods of time where the specific treatment was taken during the study, where start date = registration/consent date for treatments started before registration/consent date and/or stop date withdrawal/final date for treatments ongoing at the time of withdrawal/end of study. Where a participant has multiple records of the same therapy on the same day, the therapy is counted once for that day.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Overall Treatment Safety Population. As participant could switch between therapies a participant with an event could be allocated to more than one therapy group. Participants analyzed included who were exposed to the specific treatment any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XAGRID Taken</title>
            <description>Participants who received XAGRID from &quot;Xagrid only&quot; or &quot;Xagrid+other (cytoreductives)&quot; arm groups at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC at the time of registering into the study for a 5 year observation period.</description>
          </group>
          <group group_id="O2">
            <title>Other (Cytoreductives)-Hydroxyurea</title>
            <description>Participants who received other (Cytoreductives)-Hydroxyurea at a dose and mode of administration managed as per investigators discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O3">
            <title>Other (Cytoreductives)-Interferon Alpha</title>
            <description>Participants who received other (Cytoreductives)-Interferon Alpha at a dose and mode of administration managed as per investigators discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O4">
            <title>Other (Cytoreductives)-Pegylated Interferon</title>
            <description>Participants who received other (Cytoreductives)-Pegylated Interferon at a dose and mode of administration managed as per investigators discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O5">
            <title>Other (Cytoreductives)-Busulphan</title>
            <description>Participants who received other (Cytoreductives)-Busulphan at a dose and mode of administration managed as per investigators discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O6">
            <title>Other (Cytoreductives)-Pipobroman</title>
            <description>Participants who received other (Cytoreductives)-Pipobroman at a dose and mode of administration managed as per investigators discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O7">
            <title>Other (Cytoreductives)-Sodium Phosphate P32</title>
            <description>Participants who received other (Cytoreductives)-Sodium Phosphate P32 at a dose and mode of administration managed as per investigators discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O8">
            <title>Other (Cytoreductives)-Thromboreductin</title>
            <description>Participants who received other (Cytoreductives)-Thromboreductin at a dose and mode of administration managed as per investigators discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Participants who received other therapies at a dose and mode of administration managed as per investigators discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Exposure for Each Essential Thrombocythemia (ET) Therapy</title>
          <description>Total duration for each participant = sum of [stop date - start date + 1] across all periods of time where the specific treatment was taken during the study, where start date = registration/consent date for treatments started before registration/consent date and/or stop date withdrawal/final date for treatments ongoing at the time of withdrawal/end of study. Where a participant has multiple records of the same therapy on the same day, the therapy is counted once for that day.</description>
          <population>Overall Treatment Safety Population. As participant could switch between therapies a participant with an event could be allocated to more than one therapy group. Participants analyzed included who were exposed to the specific treatment any time during the study.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1300"/>
                <count group_id="O2" value="2742"/>
                <count group_id="O3" value="193"/>
                <count group_id="O4" value="144"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="159"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1213.7" spread="687.83"/>
                    <measurement group_id="O2" value="1382.3" spread="609.33"/>
                    <measurement group_id="O3" value="933.3" spread="748.09"/>
                    <measurement group_id="O4" value="744.0" spread="660.93"/>
                    <measurement group_id="O5" value="510.2" spread="560.28"/>
                    <measurement group_id="O6" value="992.8" spread="690.80"/>
                    <measurement group_id="O7" value="39.7" spread="96.73"/>
                    <measurement group_id="O8" value="979.0" spread="859.27"/>
                    <measurement group_id="O9" value="446.3" spread="561.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Dose for Each Essential Thrombocythemia (ET) Therapy</title>
        <description>Since the study is observational nature, interpreting the table is difficult due to inconsistencies in reporting the units of the dose.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Overall Treatment Safety Population. As participant could switch between therapies a participant with an event could be allocated to more than one therapy group. Participants analyzed included who were exposed to the specific treatment any time during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>XAGRID Only</title>
            <description>Participants who received XAGRID at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Other (Cytoreductives)-Hydroxyurea</title>
            <description>Participants who received other (Cytoreductives)-Hydroxyurea at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O3">
            <title>Other (Cytoreductives)-Interferon Alpha</title>
            <description>Participants who received other (Cytoreductives)-Interferon Alpha at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O4">
            <title>Other (Cytoreductives)-Pegylated Interferon</title>
            <description>Participants who received other (Cytoreductives)-Pegylated Interferon at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O5">
            <title>Other (Cytoreductives)-Busulphan</title>
            <description>Participants who received other (Cytoreductives)-Busulphan at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O6">
            <title>Other (Cytoreductives)-Pipobroman</title>
            <description>Participants who received other (Cytoreductives)-Pipobroman at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O7">
            <title>Other (Cytoreductives)-Sodium Phosphate P32</title>
            <description>Participants who received other (Cytoreductives)-Sodium Phosphate P32 at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O8">
            <title>Other (Cytoreductives)-Thromboreductin</title>
            <description>Participants who received other (Cytoreductives)-Thromboreductin at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O9">
            <title>Other</title>
            <description>Participants who received other therapies at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Dose for Each Essential Thrombocythemia (ET) Therapy</title>
          <description>Since the study is observational nature, interpreting the table is difficult due to inconsistencies in reporting the units of the dose.</description>
          <population>Overall Treatment Safety Population. As participant could switch between therapies a participant with an event could be allocated to more than one therapy group. Participants analyzed included who were exposed to the specific treatment any time during the study.</population>
          <units>milligram (mg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1162"/>
                <count group_id="O2" value="2168"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="112"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29096.2" spread="291472.25"/>
                    <measurement group_id="O2" value="957751.4" spread="883174.77"/>
                    <measurement group_id="O3" value="3592.2" spread="5076.77"/>
                    <measurement group_id="O4" value="5103.1" spread="10730.47"/>
                    <measurement group_id="O5" value="7749.6" spread="56031.79"/>
                    <measurement group_id="O6" value="28612.7" spread="67374.96"/>
                    <measurement group_id="O7" value="2745.0"/>
                    <measurement group_id="O8" value="2140.0" spread="835.26"/>
                    <measurement group_id="O9" value="111639.7" spread="190370.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Suspected Serious Adverse Reaction (SSAR) Events</title>
        <description>SSAR: serious adverse event (SAE) that was considered related to cytoreductive therapy. SAE: any untoward medical occurrence that at any dose resulted in death, life-threatening (at the time of the event), in-patient hospitalization/prolongation of existing hospitalization (elective hospitalizations/procedures for pre-existing conditions that had not worsened were excluded), resulted in persistent or significant disability/incapacity or congenital abnormality/birth defect. Relatedness (suspected/not suspected) to XAGRID or other cytoreductive theraphy was determined by the investigator. As for SSARs, it was important to consider whether the events were related to XAGRID or other cytoreductive therapy. A participant was included in Xagrid or other treatment group based on treatment exposure, participants received Xagrid + Other was counted both in Xagrid and other treatment group.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Overall treatment safety population. All events/data were allocated to the treatment that a participant was receiving at the time of the event/assessment. Participants who had exposed to XAGRID (alone or in combination with other) was counted in Xagrid arm and those who had received other ET therapy in the &quot;Other (Cytoreductives)&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>XAGRID</title>
            <description>Participants who received XAGRID at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years.</description>
          </group>
          <group group_id="O2">
            <title>Other (Cytoreductives)</title>
            <description>Participants who received other (Cytoreductives) at a dose and mode of administration managed as per investigator's discretion and the relevant SmPC, was observed for 5 years. Other Cytoreductives included Hydroxyurea, Interferonalpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suspected Serious Adverse Reaction (SSAR) Events</title>
          <description>SSAR: serious adverse event (SAE) that was considered related to cytoreductive therapy. SAE: any untoward medical occurrence that at any dose resulted in death, life-threatening (at the time of the event), in-patient hospitalization/prolongation of existing hospitalization (elective hospitalizations/procedures for pre-existing conditions that had not worsened were excluded), resulted in persistent or significant disability/incapacity or congenital abnormality/birth defect. Relatedness (suspected/not suspected) to XAGRID or other cytoreductive theraphy was determined by the investigator. As for SSARs, it was important to consider whether the events were related to XAGRID or other cytoreductive therapy. A participant was included in Xagrid or other treatment group based on treatment exposure, participants received Xagrid + Other was counted both in Xagrid and other treatment group.</description>
          <population>Overall treatment safety population. All events/data were allocated to the treatment that a participant was receiving at the time of the event/assessment. Participants who had exposed to XAGRID (alone or in combination with other) was counted in Xagrid arm and those who had received other ET therapy in the &quot;Other (Cytoreductives)&quot;.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1300"/>
                <count group_id="O2" value="3069"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years</time_frame>
      <desc>SSARs [defined in outcome measure (OM) 2]= SAEs considered related to cytoreductive drug and only XAGRID and Other treatment groups were to be reported. SAEs and non-SAEs was not planned to be reported separately, therefore, reported under OM 1.</desc>
      <group_list>
        <group group_id="E1">
          <title>XAGRID</title>
          <description>Participants who received XAGRID from &quot;Xagrid only&quot; or &quot;Xagrid+other (cytoreductives)&quot; arm groups (for serious adverse events) at a dose and mode of administration managed as per investigator's discretion and the relevant Summary of Product Characteristics (SmPC) at the time of registering into the study or after switching from another treatment (other adverse events) any time during the 5 year observation period.</description>
        </group>
        <group group_id="E2">
          <title>Other (Cytoreductives)</title>
          <description>Participants who received other (cytoreductives) from &quot; other (cytoreductives&quot; or &quot;Xagrid+other (cytoreductives)&quot; arm groups (for serious adverse events) at a dose and mode of administration managed as per investigator's discretion and the relevant Summary of Product Characteristics (SmPC) at the time of registering into the study or after switching from another treatment (other adverse events) any time during the 5 year observation period. Other Cytoreductives included Hydroxyurea, Interferon- alpha, Pegylated interferon, Busulphan, Pipobroman, Sodium phosphate P32.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1300"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Cardiac failure Congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome transformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Refractory anaemia with an excess of blasts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Vasculitis cerebral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3069"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3069"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results for other adverse events (excluding SAEs) was reported under OM 1 due to limitation in basic results format, as SAEs and non-SAEs were not planned to be reported separately.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>1 866-842-5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

